Home

Law Offices of Howard G. Smith Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action

via Business Wire

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). Savara investors have until November 7, 2025 to file a lead plaintiff motion.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On May 27, 2025, Savara issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) had issued a refusal-to-file letter for the Company’s Biologics License Application (“BLA”) for its autoimmune pulmonary alveolar proteinosis treatment, MOLBREEVI, determining that the submission was not sufficiently complete and requesting additional Chemistry, Manufacturing, and Controls data. That same day, Guggenheim published a report lowering its price target for Savara and warning of potential delays in commercialization and the likelihood of additional capital raises.

On this news, Savara’s stock price fell $0.90, or 31.7%, to close at $1.94 per share on May 27, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (4) the delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Savara securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Telephone: (215) 638-4847

Email: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts